1. Rosendaal FR. Venous thrombosis: a multicausal disease. Lancet. 1999; 353:1167–73
  2. Heit JA, O'Fallon WM, Petterson TM, et al. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med. 2002; 162:1245–8.
  3. Wong P, Baglin T. Epidemiology, risk factors and sequelae of venous thromboembolism. Phlebology. 2012;27 Suppl 2:2–11.
  4. Oger E. Incidence of venous thromboembolism: a community-based study in Western France. EPI-GETBP Study Group. Groupe d'Etude de la Thrombose de Bretagne Occidentale. Thromb Haemost. 2000 83:657–60.
  5. Nordström M, Lindblad B, Bergqvist D, Kjellström T. A prospective study of the incidence of deep-vein thrombosis within a defined urban population. J Intern Med. 1992 232:155–60.
  6. Silverstein MD, Heit JA, Mohr DN, Petterson TM, et al. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med. 1998; 158:585–93.
  7. Heit JA, Silverstein MD, Mohr DN, Petterson TM, et al. The epidemiology of venous thromboembolism in the community. Thromb Haemost. 2001 86:452–63.
  8. Geerts WH, Bergqvist D, Pineo GF, Heit JA et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008; 133(6 Suppl):381S-453S
  9. Kahn SR, Ginsberg JS. Relationship between deep venous thrombosis and the postthrombotic syndrome. Arch Intern Med. 2004;164:17-26.
  10. Kahn SR. The Post-Thrombotic Syndrome. Hematology Am Soc Hematol Educ Program. 2010; 2010:216-20. doi: 10.1182/asheducation-2010.1.216.
  11. van Dongen CJ, Prandoni P, Frulla M, Marchiori A, et al. Relation between quality of anticoagulant treatment and the development of the postthrombotic syndrome. J Thromb Haemost. 2005;3:939-42.
  12. Prandoni P. Healthcare burden associated with the post-thrombotic syndrome and potential impact of the new oral anticoagulants. Eur J Haematol. 2012;88:185-94.
  13. Goldhaber SZ and Bounameaux H. Pulmonary embolism and deep vein thrombosis. Lancet 2012; 379: 1835–46
  14. National Institute for Health and Clinical Excellence. Venous thromboembolic diseases: the management of venous thromboembolic diseases and the role of thrombophilia testing. Costing report. 2012
  15. Goldhaber SZ, Visani L, De Rosa M. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet. 1999; 353:1386 –1389.
  16. Piazza G and Goldhaber S. Management of Submassive Pulmonary Embolism. Circulation. 2010;122:1124–1129.
  17. Piazza G, Goldhaber SZ. Chronic thromboembolic pulmonary hypertension. N Engl J Med. 2011; 364:351–60.
  18. Isbister JP. The normal haemostatic system. Crit Care Resusc. 2008; 10:261-3
  19. Gomez K, Tuddenham EDG, McVey JH. Normal haemostasis. In Postgraduate Haematology, Sixth Edition Edited by A V. Hoffbrand, D. Catovsky, E. G. D. Tuddenham, A. R. Green © 2011 Blackwell Publishing Ltd. Chapter 29: 746–71
  20. Jerjes-Sanchez C. Venous and arterial thrombosis: a continuous spectrum of the same disease? Eur Heart J. 2005; 26:3-4
  21. Patel K. Deep Venous Thrombosis. MEDSCAPE 2014
  22. Kahn S. The post thrombotic syndrome. Thromb Res 2011; 127 Suppl. 3:S89–S92
  23. Toshner M, Pepke-Zaba J. Chronic thromboembolic pulmonary hypertension: time for research in pathophysiology to catch up with developments in treatment. F1000Prime Rep. 2014; 6:38. doi: 10.12703/P6-38. eCollection 2014.
  24. Mackman N. Triggers, targets and treatments for thrombosis. Nature. 2008 451:914–8.
  25. Weitz JI1, Gross PL. New oral anticoagulants: which one should my patient use? Hematology Am Soc Hematol Educ Program. 2012;2012:536-40. doi: 10.1182/asheducation-2012.1.536.
  26. National Institute for Health and Clinical Excellence. Venous thromboembolism: reducing the risk. 2018. NICE clinical guideline 89. Available at
  27. Risk assessment for venous thromboembolism (VTE) – NICE
  28. Institute of Obstetricians and Gynaecologists, Royal College of Physicians of Ireland and HSE Clinical Care Programme in Obstetrics and Gynaecology and Irish Haematology Society - Clinical Practice Guideline Venous Thromboprophylaxis in Pregnancy. Available at:
  29. National Institute for Health and Clinical Excellence. Venous thromboembolism prevention quality standard. 2010 NICE quality standard 3. Available at
  30. Samama M, Cohen AT, Darmon JY, et al. Comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. N Engl J Med 1999; 341:793-800.
  31. Leizorovicz A, Cohen AT, Turpie AGG, et al. Randomized, placebo controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 2004; 110:874–9.
  32. Cohen AT, Davidson BL, Gallus AS, et al. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomized placebo controlled trial. Br Med J 2006; 332:325–9.
  33. Wells PS, Forgie MA, Rodger MA. Treatment of venous thromboembolism. JAMA. 2014; 311:717–28.
  34. National Institute for Health and Clinical Excellence. Venous thromboembolic diseases: the management of venous thromboembolic diseases and the role of thrombophilia testing. 2012. NICE clinical guideline 144. Available at
  35. Enden T, Haig Y, Kløw NE, et al; CaVenT Study Group. Long-term outcome after additional catheter-directed thrombolysis vs standard treatment for acute iliofemoral deep vein thrombosis (the CaVenT study): a randomised controlled trial. Lancet. 2012; 379:31-38
  36. Othieno R, Abu Affan M, Okpo E. Home vs in-patient treatment for deep vein thrombosis. Cochrane Database Syst Rev. 2007;3(3):CD003076.
  37. Squizzato A, Donadini MP, Galli L, Dentali F, Aujesky D, Ageno W. Prognostic clinical prediction rules to identify a low-risk pulmonary embolism: a systematic review and meta-analysis. J Thromb Haemost. 2012; 10:1276–90.
  38. Carter NJ, McCormack PL, Plosker GL. Enoxaparin: a review of its use in ST-segment elevation myocardial infarction. Drugs 2008; 68:691–710.
  39. Clexane Summary of Product Characteristics
  40. Merli GJ, Groce JB. Pharmacological and clinical differences between low-molecular-weight heparins. P&T 2010; 35: 95–105.
  41. Linhardt RJ, Gunay NS. Semin Thromb Hemost 1999; 25(suppl 3):5–16.
  42. Mitton BA. Antithrombin deficiency. MEDSCAPE 2014.
  43. Barras M. Anti-Xa assays. Aust Prescr 2013; 36:98–101.
  44. Xarelto® Summary of Product Characteristics
  45. Eliquis® Summary of Product Characteristics
  46. Pradaxa® Summary of Product Characteristics
  47. NHS Deep vein thrombosis
  48. Royal College of Obstetricians and Gynaecologists. Reducing the risk of thrombosis and embolism during pregnancy and the puerperium. Available at